share_log
Account Info
Log Out

Comparing Agilon Health (NYSE:AGL) & Lisata Therapeutics (NASDAQ:LSTA)

Defense World ·  12/29/2022 14:32

agilon health (NYSE:AGL – Get Rating) and Lisata Therapeutics (NASDAQ:LSTA – Get Rating) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, earnings, institutional ownership, valuation, dividends and risk.

Risk & Volatility

agilon health has a beta of 0.78, meaning that its share price is 22% less volatile than the S&P 500. Comparatively, Lisata Therapeutics has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500.

Get agilon health alerts:

Profitability

This table compares agilon health and Lisata Therapeutics' net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
agilon health -4.30% -9.31% -5.72%
Lisata Therapeutics N/A -29.53% -27.96%

Valuation and Earnings

This table compares agilon health and Lisata Therapeutics' top-line revenue, earnings per share (EPS) and valuation.
Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
agilon health $1.83 billion 3.59 -$406.49 million ($0.26) -61.50
Lisata Therapeutics N/A N/A -$27.47 million ($12.23) -0.20

Lisata Therapeutics has lower revenue, but higher earnings than agilon health. agilon health is trading at a lower price-to-earnings ratio than Lisata Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations for agilon health and Lisata Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
agilon health 0 1 7 0 2.88
Lisata Therapeutics 0 0 2 0 3.00

agilon health presently has a consensus price target of $28.38, indicating a potential upside of 77.45%. Lisata Therapeutics has a consensus price target of $15.00, indicating a potential upside of 527.62%. Given Lisata Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Lisata Therapeutics is more favorable than agilon health.

Insider and Institutional Ownership

6.0% of Lisata Therapeutics shares are held by institutional investors. 3.3% of agilon health shares are held by insiders. Comparatively, 2.2% of Lisata Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Lisata Therapeutics beats agilon health on 7 of the 13 factors compared between the two stocks.

About agilon health

(Get Rating)

agilon health, inc. offers healthcare services for seniors through primary care physicians in the communities of the United States. As of December 31, 2021, it served approximately 238,000 senior members, which included 186,300 medicare advantage members and 51,700 medicare fee-for-service beneficiaries. The company was formerly known as Agilon Health Topco, Inc. and changed its name to agilon health, inc. in March 2021. agilon health, inc. was founded in 2016 and is based in Austin, Texas.

About Lisata Therapeutics

(Get Rating)

Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. The company was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. on September 15, 2022. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Receive News & Ratings for agilon health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for agilon health and related companies with MarketBeat.com's FREE daily email newsletter.

This presentation is for informational and educational use only and is not a recommendation or endorsement of any particular investment or investment strategy. Investment information provided in this content is general in nature, strictly for illustrative purposes, and may not be appropriate for all investors. It is provided without respect to individual investors’ financial sophistication, financial situation, investment objectives, investing time horizon, or risk tolerance. You should consider the appropriateness of this information having regard to your relevant personal circumstances before making any investment decisions. Past investment performance does not indicate or guarantee future success. Returns will vary, and all investments carry risks, including loss of principal. Moomoo makes no representation or warranty as to its adequacy, completeness, accuracy or timeliness for any particular purpose of the above content.

Moomoo is a financial information and trading app offered by Moomoo Technologies Inc.
In the U.S., investment products and services available through the moomoo app are offered by Moomoo Financial Inc., a broker-dealer registered with the U.S. Securities and Exchange Commission (SEC) and a member of Financial Industry Regulatory Authority (FINRA)/Securities Investor Protection Corporation (SIPC).
In Singapore, investment products and services available through the moomoo app are offered through Moomoo Financial Singapore Pte. Ltd. regulated by the Monetary Authority of Singapore (MAS). Moomoo Financial Singapore Pte. Ltd. is a Capital Markets Services Licence (License No. CMS101000) holder with the Exempt Financial Adviser Status. This advertisement has not been reviewed by the Monetary Authority of Singapore.
In Australia, financial products and services available through the moomoo app are provided by Futu Securities (Australia) Ltd, an Australian Financial Services Licensee (AFSL No. 224663) regulated by the Australian Securities and Investment Commission (ASIC). Please read and understand our Financial Services Guide, Terms and Conditions, Privacy Policy and other disclosure documents which are available on our websites https://www.futuau.com and https://www.moomoo.com/au. Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd. and Futu Securities (Australia) Ltd are affiliated companies.